Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
LXRX POWR Grades
- Value is the dimension where LXRX ranks best; there it ranks ahead of 39.47% of US stocks.
- The strongest trend for LXRX is in Value, which has been heading up over the past 177 days.
- LXRX ranks lowest in Momentum; there it ranks in the 4th percentile.
LXRX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for LXRX is 0 -- better than only 7.61% of US stocks.
- With a price/sales ratio of 3,149.95, LEXICON PHARMACEUTICALS INC has a higher such ratio than 99.87% of stocks in our set.
- As for revenue growth, note that LXRX's revenue has grown -53.36% over the past 12 months; that beats the revenue growth of merely 4.01% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to LEXICON PHARMACEUTICALS INC are ARGX, BTAI, PRVB, RETA, and MIRO.
- LXRX's SEC filings can be seen here. And to visit LEXICON PHARMACEUTICALS INC's official web site, go to www.lexpharma.com.
LXRX Valuation Summary
- In comparison to the median Healthcare stock, LXRX's price/sales ratio is 165668.42% higher, now standing at 3149.6.
- Over the past 243 months, LXRX's price/earnings ratio has gone down 0.6.
Below are key valuation metrics over time for LXRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LXRX | 2023-03-24 | 3149.6 | 3.7 | -4.3 | -4.5 |
| LXRX | 2023-03-23 | 3068.3 | 3.6 | -4.2 | -4.4 |
| LXRX | 2023-03-22 | 2946.0 | 3.5 | -4.0 | -4.2 |
| LXRX | 2023-03-21 | 3109.4 | 3.7 | -4.2 | -4.4 |
| LXRX | 2023-03-20 | 3068.3 | 3.6 | -4.2 | -4.4 |
| LXRX | 2023-03-17 | 3054.7 | 3.6 | -4.2 | -4.4 |
LXRX Growth Metrics
- Its 3 year revenue growth rate is now at -99.35%.
- Its 5 year net cashflow from operations growth rate is now at 153.99%.
- The year over year cash and equivalents growth rate now stands at -39.05%.
The table below shows LXRX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.125 | -90.11 | -97.061 |
| 2022-06-30 | 0.109 | -87.821 | -96.796 |
| 2022-03-31 | 0.308 | -85.279 | -90.276 |
| 2021-12-31 | 0.298 | -87.017 | -87.758 |
| 2021-09-30 | 0.483 | -98.428 | -67.642 |
| 2021-06-30 | 7.094 | -121.656 | 38.083 |
LXRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LXRX has a Quality Grade of D, ranking ahead of 14.8% of graded US stocks.
- LXRX's asset turnover comes in at 0.038 -- ranking 340th of 681 Pharmaceutical Products stocks.
- SEEL, AVEO, and OTLK are the stocks whose asset turnover ratios are most correlated with LXRX.
The table below shows LXRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.038 | 0.911 | 2.792 |
| 2021-03-31 | 0.071 | 0.915 | -0.037 |
| 2020-12-31 | 0.089 | 0.920 | -0.233 |
| 2020-09-30 | 0.101 | 0.917 | -0.269 |
| 2020-06-30 | 0.824 | 0.992 | 0.131 |
| 2020-03-31 | 0.875 | 0.990 | 0.239 |
LXRX Price Target
For more insight on analysts targets of LXRX, see our LXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $12.50 | Average Broker Recommendation | 1.67 (Moderate Buy) |
LXRX Stock Price Chart Interactive Chart >
LXRX Price/Volume Stats
| Current price | $2.37 | 52-week high | $3.48 |
| Prev. close | $2.32 | 52-week low | $1.31 |
| Day low | $2.31 | Volume | 270,800 |
| Day high | $2.42 | Avg. volume | 400,775 |
| 50-day MA | $2.31 | Dividend yield | N/A |
| 200-day MA | $2.36 | Market Cap | 447.28M |
Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.
Latest LXRX News From Around the Web
Below are the latest news stories about LEXICON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LXRX as an investment opportunity.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Call TranscriptLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Call Transcript March 3, 2023 Operator: Good afternoon, and welcome to the Lexicon Pharmaceuticals Fourth Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. I would […] |
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of CardiologyStatistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection fraction (LVEF) range THE WOODLANDS, Texas, March 04, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational product sotagliflozin presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With Wo |
Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following HospitalizationInto the Dark Into the Dark Campaign Image Emphasizes challenges faced by patients and clinicians within the first 30 days after discharge from a heart failure hospitalization Reinforces impact of rehospitalizations for heart failure patients and healthcare system Campaign launches at American College of Cardiology’s 72nd Annual Scientific Session Together with World Congress of Cardiology THE WOODLANDS, Texas, March 04, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), toda |
Q4 2022 Lexicon Pharmaceuticals Inc Earnings CallQ4 2022 Lexicon Pharmaceuticals Inc Earnings Call |
Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateNDA for Sotagliflozin on Track for May 2023 PDUFA date following Late-Cycle Review Meeting LX9211 Demonstrates Consistent Results in Full Data from RELIEF-DPN-1 in Diabetic Peripheral Neuropathic Pain and Top-Line Data from RELIEF-PHN-1 in Post-Herpetic Neuralgia Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, March 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended Decembe |
LXRX Price Returns
| 1-mo | 5.33% |
| 3-mo | 24.08% |
| 6-mo | -1.25% |
| 1-year | 12.86% |
| 3-year | 26.06% |
| 5-year | -72.35% |
| YTD | 24.08% |
| 2022 | -51.52% |
| 2021 | 15.20% |
| 2020 | -17.59% |
| 2019 | -37.50% |
| 2018 | -32.79% |
Continue Researching LXRX
Want to do more research on Lexicon Pharmaceuticals Inc's stock and its price? Try the links below:Lexicon Pharmaceuticals Inc (LXRX) Stock Price | Nasdaq
Lexicon Pharmaceuticals Inc (LXRX) Stock Quote, History and News - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...